When was Astraveus founded?

Astraveus was founded in 2016 and raised its 1st funding round 3 years after it was founded.

Where is Astraveus located?

Astraveus is headquartered in Paris, France.

Who is the current CEO of Astraveus?

Jeremie Laurent of Astraveus. They have also founded 1 company.

How many employees does Astraveus have?

As of Aug 31, 2026, the latest employee count at Astraveus is 64.

Is Astraveus a funded company?

Astraveus is a funded company, having raised a total of $18M across 5 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Mar 01, 2019.

When was the latest funding round of Astraveus?

Astraveus' latest funding was a $***** Grant (prize money) round on Dec 19, 2024, with participation from 1 investor. Its primary sector is Life Sciences Platforms and Tools. In France, the Life Sciences Platforms and Tools sector has seen $17M in funding in 2026 to date.

Where does Astraveus rank among its competitors?

Astraveus ranks 5th amongst 34 active competitors, of which 10 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Cellares, which secured $50M in Jun, 2026.

Who are the top competitors of Astraveus?

Astraveus' top competitors include Multiply Labs, Oribiotech and Cellares. Among them, Cellares secured the most recent funding round in June, 2026.

Astraveus - 2026 Company Profile, Team, Funding & Competitors

Astraveus is a seed company based in Paris (France), founded in 2016 by Jeremie Laurent. It operates as a Provider of a device for autologous cell and gene therapies. Astraveus has raised $18M in funding from AdBio partners. The company has 34 active competitors, including 10 funded and 2 that have exited. Its top competitors include companies like Multiply Labs, Oribiotech and Cellares.

Company Details

Provider of a device for autologous cell and gene therapies. The company focuses on building high-tech equipment to manufacture autologous cell and gene therapies which include CAR-T or stem cell treatments. The company has developed Lakhesys a microfluidic technology to develop cellular therapies for various disease conditions.

Website: www.astraveus.com/
Social
Email ID: *****@astraveus.com, *****@astraveus.com

Key Metrics

Founded Year

2016

Location

Paris, France

Stage

Seed

Total Funding

$18M in 5 rounds

Latest Funding Round

Grant (prize money), Dec 19, 2024, $*****

Investors

AdBio partners & 6 more

Ranked

5^th among 34 active competitors

Employee Count

64 as on Aug 31, 2026

Similar Companies

Multiply Labs & 33 more

View Astraveus' full profile

Astraveus has raised a total funding of $18M over 5 rounds. Its first funding round was on Mar 01, 2019. Its latest funding round was a Grant (prize money) round on Dec 19, 2024 for $*****. 1 investor participated in its latest round. Astraveus has 7 institutional investors.

Here is the list of recent funding rounds of Astraveus:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 19, 2024	2991338	Grant (prize money)	6453298	4185582	4699605	2452191
Oct 24, 2023	7154693	Grant (prize money)	2134558	2358486	7381584	Government of France
Jun 27, 2023	9251474	Seed	6591675	7675300	AdBio partners	M Ventures & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Astraveus's funding rounds and investors

The founders of Astraveus is Jeremie Laurent. Jeremie Laurent is the CEO of Astraveus.

Here are the details of Astraveus' key team members:

Jeremie Laurent: Founder & CEO of Astraveus.
Contact Info: 1 email address
Andrew Shailer Smith: ex-CEO of Astraveus.

View details of Astraveus's Founder profiles and Board Members

Astraveus' employee count trend

Astraveus has 64 employees as of Aug 26. Here is Astraveus's employee count trend over the years:

Uncover Astraveus' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Astraveus include Multiply Labs, Oribiotech and Cellares. Here is the list of Top 10 competitors of Astraveus, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Multiply Labs 2016, San Francisco (United States), Series A	Manufacturer of precision medicines through innovative robotic technology	$41.3M	Zillionize, Casdin Capital & 22 others	69/100
2nd	Oribiotech 2015, London (United Kingdom), Series B	Biotech company focused on advancing cell and gene therapy manufacturing through innovative automation tool	$281M	Northpond Ventures, Novalis LifeSciences ... & 17 others	66/100
3rd	Cellares 2019, San Francisco (United States), Series D	Manufacturer of a medical device for cell-based therapy	$682M	Eclipse, Decheng Capital & 17 others	64/100
4th	Cellular Origins 2022, Melbourn (United Kingdom), Series A	Provider of automated manufacturing solution for cell and gene therapy	$40M	Johnson & Johnson, The Technology Partnership ... & 3 others	59/100
5th	Astraveus 2016, Paris (France), Seed	Provider of a device for autologous cell and gene therapies	$18M	EIC Fund, Johnson & Johnson Innovation & 5 others	55/100
6th	Unicorn Biotechnologies 2020, Sheffield (United Kingdom), Seed	Developer of bioreactors for cell-based manufacturing	$3.45M	Acequia Capital, Climate Capital & 9 others	44/100
7th	Shenzhen Shenyan Biotechnology 2014, Shenzhen (China), Series B	Developer of automated cell processing system	$56.7M	Eight Roads Ventures, Tasly & 4 others	40/100
8th	ThermoGenesis 1986, Rancho Cordova (United States), Public	Provider of automated technologies for cell-based therapeutics and bio-processing	-	Bay City Capital, HHS	40/100
9th	Celltrio 2018, Fremont (United States), Series B	Developer of automated biobanking and cell culture systems	$15M	Premier Partners, Asia2G Capital	39/100
10th	Cell X Technologies 2017, Cleveland (United States), Funding Raised	Developer of regenerative medicine to measure and manage human cell sources	-	Innovation Works, Denniston Family Office ... & 2 others	35/100